Blade Therapeutics Vote Delayed

by | Jun 3, 2022

The race against the clock continues, with BIOT the latest SPAC looking for more time. And the rest of the day’s news in SPACs.

————————————————-
Free Investor Resources from Boardroom Alpha
—————————————————-
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

BIOT / Blade Therapeutics: Vote Delayed

Biotech Acquisition Company (BIOT) delays vote on merger with Blade Therapeutics. The SPAC indicates it has have enough votes for approval, but needs more time to satisfy all necessary closing conditions. “As of the date of this press release, a sufficient number of BAC’s shareholders have voted to approve the proposed business combination. The postponement of the Extraordinary Meeting is intended to permit more time to satisfy all conditions necessary to effect the closing of the proposed Business Combination.” New date TBD.

OTEC Extends Deadline

OceanTech Acquisitions I Corp. (OTEC) extends deadline by six months to December 2022. SPAC contributes $0.15 per share to trust ($1,548,900).

Elsewhere in SPACs

  • 26 Capital Acquisition Corp. (ADER) sets vote date for June 28. The SPAC has a DA with UERI, the holding company of Okada Manila, one of the premier casino resorts in Asia and the largest integrated resort in the Philippines.

Boardroom Alpha SPAC Market Review for May

Time is running out as SPACs scramble to finance deals at almost any cost. Expect more deSPAC duds as sponsors push low-quality companies at onerous valuations — for the simple purpose of protecting at-risk capital. Full report here.

SPAC Calendar

Source: Boardroom Alpha

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

Recent Analysis

CEO & CFO Moves Review (Sept 6)

This week’s moves include CEO and CFO changes include moves at Accuray Inc. (ARAY), Atlassian Corporation (TEAM), Azenta Inc. (AZTA), Bloomin’ Brands, Inc. (BLMN), Chipotle Mexican Grill, Inc. (CMG), Fossil Group, Inc. (FOSL), NovoCure Limited (NVCR), and Repligen Corporation (RGEN).

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.